Alumis Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates
Globe Newswire•12/11/2026•16:05 ET
0
Key Highlights
- ➤Psoriasis Phase 3 data showed 54% PASI 100 response at Week 48
- ➤Alumis remains on track for fourth-quarter 2026 psoriasis NDA submission
- ➤LUMUS Phase 2b SLE trial missed primary and secondary endpoints overall
- ➤Alumis held $431.3 million in cash, equivalents and marketable securities
- ➤Third-quarter net loss narrowed to $94.9 million from $110.8 million
Expert Statements
Martin Babler, President and Chief Executive Officer of Alumis
“Each additional readout from the ONWARD program has strengthened the consistent body of evidence supporting envudeucitinib’s highly competitive profile in moderate-to-severe plaque psoriasis”
Martin Babler, President and Chief Executive Officer of Alumis
“The new data presented in October showed early and durable improvement across scalp disease severity, itch resolution, and quality of life measures, building on a 54% PASI 100 response rate observed at 48 weeks.”
Martin Babler, President and Chief Executive Officer of Alumis
“Our fourth-quarter 2026 NDA submission remains on track.”
– New Phase 3 data demonstrated rapid and durable improvements in plaque psoriasis burden, adding to envudeucitinib's differentiated clinical profile, including the highest publicly reported Week 48 PASI 100 response rate among existing and investigational oral psoriasis therapies –
– Alumis remains on track to submit an NDA for envudeucitinib in moderate-to-severe plaque psoriasis in 4Q 2026 –
Get started
Create a free account to read the full story.